Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has shared an announcement.
JCR Pharmaceuticals has revised its consolidated forecast for the fiscal year ended March 31, 2026, projecting higher net sales of ¥39.5 billion, up 4.5% from its previous estimate, driven mainly by stronger-than-expected demand for therapies for renal anemia and Fabry disease as well as higher license and other revenues. Despite this top-line improvement, the company now expects operating and ordinary profits to fall sharply to ¥400 million and net profit attributable to owners of the parent to drop to ¥1.6 billion, reflecting increased cost of sales, higher R&D spending tied to an upfront payment for the exclusive Japan license of givinostat from Italfarmaco, and greater selling, general and administrative expenses including depreciation at its Kobe Science Park Center API facility; dividend guidance remains unchanged, suggesting commitment to shareholder returns even as profit margins are pressured by strategic investment and cost factors.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen705.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty biopharmaceutical company focused on developing and commercializing therapies for rare and genetic diseases, building on a 50-year legacy in Japan while expanding into the U.S., Europe, and Latin America. Its approved portfolio in Japan includes treatments for growth disorders, MPS II (Hunter syndrome), Fabry disease, acute graft-versus-host disease, and renal anemia, and it is advancing a pipeline of next-generation therapies for multiple lysosomal storage and other rare disorders.
Average Trading Volume: 975,166
Technical Sentiment Signal: Hold
Current Market Cap: Yen83.9B
For detailed information about 4552 stock, go to TipRanks’ Stock Analysis page.